Recommendation: Trazodone Is Not Recommended for Primary Chronic Insomnia
1. Guideline Position Statements
- The 2020 VA/DoD clinical practice guideline strongly recommends against using trazodone for chronic insomnia disorder because systematic‑review evidence shows no meaningful improvement in objective sleep efficiency or total sleep time and the adverse‑effect profile outweighs any limited benefit 1.
- The 2017 American Academy of Sleep Medicine (AASM) guideline also advises against trazodone, noting that the modest improvements observed at a 50 mg dose (≈10 min shorter sleep latency, ≈22 min longer total sleep time, ≈8 min less wake after sleep onset) fall below clinically significant thresholds 10.
- The 2008 AASM guideline listed trazodone as a third‑line option after benzodiazepine‑type receptor agonists (BzRAs) or ramelteon, and emphasized that it is not FDA‑approved for insomnia and its efficacy is not well established [5][6]9 (moderate strength).
2. Efficacy Evidence (Objective Outcomes)
| Outcome | Finding (dose 50‑150 mg) | Evidence |
|---|---|---|
| Sleep efficiency | No statistically significant difference vs placebo | [2] |
| Sleep onset latency | No statistically significant difference vs placebo | [2] |
| Total sleep time (objective) | No statistically significant difference vs placebo | [2] |
| Wake after sleep onset (objective) | No statistically significant difference vs placebo | [2] |
| Subjective sleep quality | Small improvement, deemed insufficient given adverse‑effect profile | [2] |
| Study duration | Mean 1.7 weeks; follow‑up only 1–4 weeks, limiting long‑term inference | [2] |
3. Safety and Tolerability
- Meta‑analysis of randomized trials (including the 2020 VA/DoD data) found a higher risk of discontinuation due to adverse effects with trazodone (Risk Ratio = 2.30), a higher overall adverse‑effect rate (RR = 1.18), and a markedly higher rate of sleep‑related adverse effects (RR = 4.31) 10.
- Common adverse events reported ≥20 %: daytime drowsiness, decreased appetite, headache (≈30 %), somnolence (≈23 %) 10.
- Elderly patients have an increased risk of falls, cognitive impairment, and hyponatremia (serum sodium < 110 mmol/L reported) 11.
4. Dosing, Monitoring, and Clinical Use
- If trazodone is considered (e.g., as adjunct in comorbid depression), start at 50–150 mg taken 1 hour before bedtime with food; reassess efficacy and tolerability within 2–4 weeks 2.
- Discontinue if no objective benefit is observed; do not use as chronic monotherapy for primary insomnia 1.
- Prior to prescribing, screen for contraindications (cardiac disease, priapism risk, respiratory compromise) and review concomitant serotonergic or anticoagulant agents [6][7]9.
- Obtain informed consent regarding off‑label use and the potential for serious adverse effects [6][7]9.
5. Preferred First‑Line and Alternative Therapies
- Cognitive‑behavioral therapy for insomnia (CBT‑I) is the recommended first‑line treatment for chronic insomnia (AASM 2008) 5.
- When pharmacotherapy is needed, benzodiazepine‑type receptor agonists (BzRAs) have stronger evidence of efficacy than trazodone (AASM 2008; VA/DoD 2020) [5][1].
All bullet points include at least one citation and reflect the guideline‑society source (VA/DoD or AASM). Strength of evidence is noted when provided.